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Enterovirus D68 (EV-D68) causes severe respiratory illness outbreaks among children, particularly those with
asthma. We previously detected neutralizing antibodies
against the predominant EV-D68 B1 clade in the 2014
outbreak in serum collected before the outbreak (2012–
2013) from persons 24 months to 85 years of age. We
recently detected neutralizing antibodies to the 2014
B1, B2, and D clade viruses in serum collected after the
2014 outbreak (April–May 2017) from 300 children 6
months to 18 years of age. B1 virus neutralizing antibodies were found in 100% of patients, even children born
after 2014; B2 in 84.6%, and D in 99.6%. In 2017, titers
increased with patient age and were higher than titers
in 2012–2013 from comparably aged children. Rate of
seronegativity was highest (15.3%) for B2 virus. Multivariate analysis revealed an association between asthma and higher titers against B2 and D viruses. EV-D68
seems to have circulated during 2014–2017.

E

nterovirus D68 (EV-D68) rose to prominence because of its association with acute flaccid myelitis
(AFM) (1,2) and the US outbreak of severe respiratory
disease among children in 2014 (381 cases in Kansas
City, Missouri, USA; 1,153 confirmed cases nationally). Severe disease affected children with a history of
atopic disease, asthma, or reactive airway disease (3–
6). Although the 2014 EV-D68 outbreak in the United
States was caused predominantly by a clade B1 virus,
2 less frequent viruses, clades B2 and D (previously
A2), were also detected. In the United States, EV-D68
activity varies year to year and regionally; some areas show a biennial pattern and others do not (7), yet
EV-D68 seems to be seasonal (primarily late summer
through fall).
Before 2014, sporadic small regional/local EVD68 outbreaks were reported in the United States (8)
and globally. However, during 2014–2016, EV-D68
was the most frequently reported enterovirus in the
United States (9). Prevalence of nonoutbreak cases
is unclear; however, new B clade viruses emerged
in 2012 and 2013 (10–12), and new B subclade and
D clade viruses emerged in 2016–2019 (12). In contrast to other US regions, activity in Kansas City was
minimal in 2015 (7), 2016, and 2017 (R. Selvarangan,
unpub. data).
Prospective EV-D68 surveillance has recently been
undertaken by the New Vaccine Surveillance Network
(NVSN, https://www.cdc.gov/surveillance/nvsn/
index.html), which includes Kansas City. NVSN reported an uptick in activity in July and October 2018
(13) in not only Missouri (54 detections in Kansas City,
clade B3 [14]) but also Ohio, Tennessee, Pennsylvania,
Texas, Washington, and New York. Clade B3 virus in
Kansas City was similar to the virus that caused a 2016
2

outbreak associated with AFM in nonmidwestern US
areas. Nevertheless, increased worldwide attention
has led to seroprevalence and genotyping reports from
multiple countries (15–20).
EV-D68 community circulation remains underrecognized because clinically used multiplex respiratory PCR assays do not specifically identify EVD68. We previously evaluated EV-D68 neutralizing
antibodies in serum collected in Kansas City during
2012–2013 from persons 2–85 years of age (21). Despite no prior documented EV-D68 outbreaks or outbreaks of EV-D68 compatible illnesses in Kansas City,
all samples had neutralizing antibodies to the B1 virus, suggesting EV-D68 circulation before the major
outbreak in 2014.
Our goals with this study were to use the same
assay that we used previously to evaluate neutralizing EV-D68 antibodies to the 2014 clade B1, B2, and D
viruses in serum collected during 2017 from children
6 months to 18 years of age, including those born after
2014, and to examine associations of antibody titers
with demographic and medical history factors. This
study was approved by the institutional review board
at Children’s Mercy Hospital Kansas City.
Methods
We examined deidentified serum from 300 nonimmunocompromised children 6 months to 18 years of
age in Kansas City for EV-D68 neutralizing antibodies.
Samples were taken from excess serum after standardcare phlebotomy during April–May 2017 (Appendix,
https://wwwnc.cdc.gov/EID/article/28/3/21-1467App1.pdf). We matched age, sex, and race distributions with those from 2016 Kansas City pediatric census data (10). We used the following age groups: 6–35
months of age (n = 76) born after September 2014 (postoutbreak), 36–71 months (n = 51), 72 months–10 years
(n = 70), 11–15 years (n = 69), and >15 years (n = 34). We
excluded serum from children younger than 6 months
because of confounding transplacentally acquired maternal EV-D68 antibodies. We used electronic medical
records to document patient age, sex, race, family size,
underlying conditions, and number of both hospitalizations and of chest radiographs in the prior 3 years.
The Centers for Disease Control and Prevention
(CDC; Atlanta, Georgia, USA) performed serologic
testing for this study, using the same microneutralization assay as in our previous study, adapted from
a standardized polio antibody assay (22,23). Three
phylogenetically distinct EV-D68 viruses were used:
2014 Missouri 14-18949 (clade B1, GenBank accession
no. KM851227); and 2 non-Missouri 2014 strains 1418952 (clade B2, GenBank accession no. KM851230)
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and 14-18953 (clade D, formerly A2, GenBank accession no. KM851231). The 2014 detection frequency
among US patients was >91% for B1, 7.4% for B2, and
<2% for D viruses (10).
This EV-D68 microneutralization assay performed at CDC was previously published (21,24,25).
In brief, 2-fold serum dilutions, 1:8 to 1:1,024, were
combined with 100 cell culture 50% infectious doses
of EV-D68 to enable antibody to bind to virus. After 3 hours of incubation, each virus–serum mixture
was inoculated onto rhabdomyosarcoma (CCL-136;
American Type Culture Collection, https://www.
atcc.org) cell monolayers. CDC tested each serum
dilution in triplicate against each virus. Each run
had known positive control serum (horse antibodies
against the Fermon prototype EV-D68 virus); multiple (>4) positive control replicates were distributed
across each run. When >7 serum samples were tested
in the same run, sample position was randomized via
a balanced block randomization scheme. Each run included 2 control plates with no serum or control antibodies; rhabdomyosarcoma cells alone served as a
no-virus control. A back-titration virus–control plate
was used for each of the 3 EV-D68 strains to confirm
the amount of antigen used in each run. A luminescent cell viability kit (ATPlite; Perkin Elmer, http://
www.perkinelmer.com) was used to evaluate neutralization, and samples with luminescent activity at
a titer of >3 log2 (1:8 dilution) were considered to be
positive for neutralizing antibodies (21,24,25).
We performed statistical analyses by using Sigmaplot version 12.2 (http://www.sigmaplot.co.uk) for
univariate and multivariate analyses; we considered
p<0.05 to be significant. We assigned a value of log2
2.5 to seronegative samples. We did not analyze ethnicity and daycare attendance because of incomplete
data. Categorical values were analyzed by using the χ2
test. We analyzed antibody titers by using the KruskalWallis rank-sum test to determine if overall distributions’ medians significantly differed among groups,
and we performed subset comparisons by using the
Kolmogorov-Smirnov test. We assessed differences
between viruses in each age group by using nonparametric analysis of variance and adjusted for multiple
comparisons by using Tukey-Kramer comparisons.
To determine whether responses differed between
children born after the outbreak and in the year of the
outbreak, we used a subset analysis of variance to compare titers for children born in 2014, 2015, and 2016.
We presented comparisons of antibody titer distributions as reverse cumulative distributions (RCD;
Appendix). We compared areas under the curve
(AUCs) of the RCD curves for each age group among

3

viruses and for each virus among age groups, to represent overall population neutralizing antibody responses by age group (Figure) and by virus (Appendix Figure).
For univariate analysis of demographic and underlying condition data, we used the Mann-Whitney
rank sum or the Kruskal-Wallis test, as appropriate.
We then used multivariable logistic regression based
on binary outcome of high versus low titer to analyze
factors significant by univariate analyses.
Results
Samples were from 300 patients with a median age
of 6.0 years (range 0.5–17.9 years), and 152 (51%) patients were male. Self-reported race/ethnicity from
medical records indicated that 200 (66.6%) patients
were White, 49 (16.3%) Black, 45 (15.0%) mixed/
other, 6 (2%) Asian, 6 (2.0%) Native American, and
1 Micronesian. In total, 33 patients self-reported as
Hispanic/Latino and 8 were listed as non-Hispanic/
Latino; ethnicity was not available in the medical records for 259 (86.3%) patients. Families can opt out
of reporting ethnicity when registering at our institution. Family size averaged 4.4 ± 1.1 members. Overall, the mean number of hospital admissions in the
previous 3 years was 1.4 ± 1.1 (range 0–6). Underlying
conditions were reported for 130 (43.3%): asthma, 39
(13.0%); neurologic disease, 25 (8.3%); diabetes mellitus, 16 (5.3%); cardiac disease, 15 (5%); renal disease,
13 (4.3%); other lung conditions, 6 (2.0%); blood disorder not cancer, 6 (2.0%); and other disease (hepatic,
metabolic, other endocrine), 10 (3.3%).
In all 300 samples, neutralizing antibodies against
B1 virus were detected (i.e., >3 log2, 1:8 titer) (Table 1).
Seropositive rates were lower for B2 (254/300, 84.7%)
than for B1 (100%) or D virus 296/300 (98.7%; p<0.001
for each).
More samples were seronegative for B2 (n = 76)
than for D virus (n = 6). Male patients were overrepresented among those seronegative for B2 virus,
65% (30/46) compared with the overall sample set,
for which 48% (122/254) were male (odds ratio 2.029,
95% CI 1.054–3.905; p = 0.03). For the B2 virus, the seronegative rate was higher (25/76, 32.9%) among patients 6–35 months of age (all born after the 2014 outbreak) than among those >36 months of age (21/224,
9.4%) and born before the 2014 outbreak. Two patients 6–35 months of age were seronegative for both
B2 and D viruses. Seronegative rates did not differ by
race (data not shown).
Median neutralizing titers rose with advancing
age (p<0.001; Table 1), but titers among patients 11–15
years of age were similar to those among patients >15
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Figure. Reverse cumulative distribution (RCD) curves of enterovirus D68 (EV-D68) representing the distribution of neutralizing antibody
titers against 3 EV-D68 viruses (clades B1, B2, and D) in serum samples obtained in 2017 from children <18 years of age in Kansas
City, Missouri, USA, by patient age group. A) 6–35 months of age; B) 36–71 months of age; C) 72 months–10 years of age; D) 11–15
years of age; E) 16–18 years of age. A titer >3.0 log2 was considered positive for neutralizing antibodies. RCDs are curves for which
each data point is the proportion of the population with a titer at least as high as the value on the x-axis. The calculated values for each
area under curve (AUC) enable comparison of overall immune responses among age groups. Each panel shows 3 RCDs (1 for each
virus). Panel A shows that the widest divergence of curves occurred among patients 6–35 months of age, who were born after the 2014
outbreak, suggesting less cross-neutralization among the 3 related viruses in this age group. RCDs become more convergent with each
increasing age group. The largest AUCs in each age group are for the B1 predominant 2014 outbreak virus.

years of age. The overall median titer was highest for
B1 viruses (9.17 log2, range 5.5–10.5 log2) and lowest
for D viruses (7.5 log2, range 2.5–10.5 log2; p<0.001).
We found no significant differences in median titers
for any of the 3 viruses between children born in 2014,
2015, or 2016 (data not shown). Overall, neutralizing
titers did not differ by sex, race, or family size (data
not shown).
Patients 8–13 years of age, whose samples were
obtained in 2017, would have been 5–10 years of age
(the age group previously documented to have had
4

the most severe disease) in 2014 (21). The median B1
virus titer for those 8–13 years of age in 2017 is higher
(9.83, interquartile range [IQR] 9.5–10.5) than titers
for those who were either 8–13 (8.17, IQR 5.83–9.83)
or 5–10 (7.83, IQR 4.17–10.5) years of age in 2012–2013
(21). Likewise, low titers were more frequent in serum collected in 2012 than in 2017 (Table 2).
RCD curves show differences in the distribution of 5 age groups of patients (Figure); titers of
neutralizing antibodies against the 3 viruses targeted in the neutralization assays are expressed along
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Table 1. Serum neutralizing antibody positivity and titers for enterovirus D68 clades B1, B2, and D, by patient age group, Kansas City,
Missouri, USA, 2017
% Neutralizing antibody positive, median (range) neutralizing antibody titer*
Age group
No. patients
B1 clade virus
B2 clade virus
D clade virus
6–35 mo
76
100, 7.83 (5.50–10.5)
76.9, 3.17 (2.5–10.5)
98.1, 5.5 (2.5–9.83)
36–71 mo
51
100, 9.17 (6.17–10.5)
89.8, 6.00 (2.5–10.5)
100, 6.5 (3.5–10.5)
72 mo−10 y
70
100, 9.50 (6.50–10.5)
96.7, 8.83 (2.5–10.5)
99.5, 8.17 (2.83–10.5)
11–15 y
69
100, 10.17 (6.5–10.5)
99.3, 10.17 (2.5–10.5)
100, 10.17 (3.83–10.5)
>15 y
34
100, 10.5 (5.83–10.5)
100, 10.50 (5.5–10.5)
100, 10.5 (4.5–10.5)
Total
300
100, 9.17 (5.5–10.5)
84.6, 7.83 (2.5–10.5)
99.6, 7.50 (2.5–10.5)
*Antibody titers were measured by using the cell viability kit ATPlite (Perkin Elmer, http://www.perkinelmer.com); the titers shown are the log2 inverse
dilution of the lowest antibody concentration with luminescent activity. Seronegative patients are included.

the x-axis. We calculated AUCs and used them for
comparative analyses.
The RCDs for the 3 viruses became less divergent with advancing age group. RCD curve AUCs
for B1 were larger than those for B2 or for D viruses in the 3 younger age groups, (p<0.001 for each).
Within the 2 older age groups, RCD profiles did not
differ significantly.
When we evaluated the RCDs for each of the 3
viruses (Appendix Figure) for the 5 age groups, overall RCDs were larger for B1 than for B2 or D viruses
(p<0.01). RCD AUCs for each virus became larger
with advancing age groups (i.e., smallest for those
6–36 months of age and largest for those >15 years
of age). For each virus, RCD differences were most
notable for the 3 youngest age groups. Indeed, RCD
curves for the 11-15–year age group and the >15 years
age group were larger than curves for the 3 younger
age groups (p<0.001 for each virus; Appendix Figure).
We performed univariate analysis for associations by using median titer differences. We noted significant differences for patients with asthma (higher
median titer 10.17 [IQR 9.17–10.5] vs. 9.17 [IQR 7.83–
10.17]; p = 0.001) by univariate analysis (Table 3). Median titers were higher for those who had been hospitalized during the previous 3 years (p = 0.036) but not
for the subset admitted specifically for respiratory illness. Other associated factors, but with lower median
titers, were chronic nonasthma lung disease (lower
median titer 7.17 [IQR 6.75–8.83] vs. 9.5 [IQR 8.09–
10.17]; p = 0.01), congenital heart disease (lower median titer 8.17 [IQR 7.17–8.5] vs. 9.5 [IQR 8.17–10.5];

p = 0.02), and a chest radiograph performed in the
previous 3 years (p<0.001). Two factors, daycare attendance and ethnicity, were not analyzed because of
insufficient patient numbers with data documented
in the medical record. For analyzed underlying conditions, no differences were associated with diabetes
mellitus, other endocrine disorders, hematologic illness (immune-compromising conditions were excluded), neurologic, renal, hepatic, or metabolic diseases (data not shown)
Multivariate analysis based on binary categorization (high vs. low titer) and using variables that were
significant in univariate analyses revealed persistent
significance for a history of asthma (higher titers).
However, when we excluded children <24 months of
age from the analysis (given that titers are associated
with age and no patient in the asthma group was <24
months of age), significantly higher titers persisted
for B2 and D viruses only (Appendix Table).
Discussion
All samples, even from children born after the 2014
outbreak and as young as 6 months, contained EVD68 neutralizing antibodies to the 2014 outbreak B1
virus. This finding indicates that the outbreak virus, or a closely related EV-D68 strain, circulated in
Kansas City from 2014 through 2017. EV-D68 was
not detected in the clinical or research laboratory
at Children’s Mercy Hospital Kansas City during
2015 or 2017 from research surveillance or clinical
samples obtained from children receiving medical
care at that hospital. Yet EV-D68 activity in Kansas

Table 2. Low versus high neutralizing antibody titers for enterovirus D68 clades B1, B2, and D in serum collected in 2017 compared
with titers previously reported from 2012–2013, from patients <18 years of age, Kansas City, Missouri, USA*
No. (%) patients
Group
Total
B1 clade virus
B2 clade virus
D clade virus
Serum obtained in 2017
300
Low titer†
0
110 (36.7)
66 (22.0)
High titer
300 (100)
190 (63.3)
234 (78.0)
Serum obtained in 2012–2013 (18)
273
Low titer†
54 (19.8)
117 (42.9)
133 (48.7)
High titer
219 (80.2)
156 (57.1)
140 (51.3)
*Antibody titers were measured by using the cell viability kit ATPlite (Perkin Elmer, http://www.perkinelmer.com). Seronegative patients are included.
†Low neutralizing titer defined as <6 log2 (<1:64 titer).
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Table 3. Neutralizing antibody titers for enterovirus D68 clades B1, B2 and D, in patients >24 months of age with and without a clinical
diagnosis of asthma, Kansas City, Missouri, USA, 2017
Neutralizing antibody, median (range)*
Group
No. patients
B1
B2
D
Asthma†
39
9.83 (5.50–10.50)
9.17 (2.50–10.50)
9.17 (3.17–10.50)
No asthma
214
9.50 (5.83–10.50)
8.83 (2.50–10.50)
8.17 (2.50–10.50)
Total
253
9.50 (5.50–10.50)
9.17 (2.50–10.50)
8.83 (2.50–10.50)

*Antibody titers were measured by using the cell viability kit ATPlite (Perkin Elmer, http://www.perkinelmer.com); the titers shown are the log2 inverse
dilution of the lowest antibody concentration with luminescent activity. Includes seronegative patients.
†Asthma as noted by clinician diagnosis in electronic medical record. Because no patients had an asthma diagnosis at <24 mo of age, to balance the age
distributions of the nonasthma group with the asthma age group, we excluded nonasthma patients <24 mo of age from this analysis.

City after, and presumably during, 2014 may have
contributed to the higher titers in samples collected in spring 2017 compared with titers in samples
collected in 2012 from children of comparable ages.
EV-D68 was detected in 11 routine clinical samples
in 2016 and in 255 NVSN research samples collected
in 2018 (13), but the 2018 detections were all later
than the April 2017 date of the samples in our study.
Furthermore, excess hospital admissions for severe
respiratory disease, particularly intensive care unit
admissions, such as had been noted in 2014, were
infrequent among children seeking care at our Kansas City institution during 2015–2017 (C.J. Harrison,
unpub. data). The only outbreak detected in Kansas
City after the 2014 outbreak was caused by a B3 virus
in 2018 (13) (a national EV-D68 outbreak occurred in
2018 and was associated with increased reports of
AFM and emergency department visits/hospitalizations for EV-D68 respiratory illnesses) (13).
Our data also confirm age-associated higher
titers (e.g., generally increasing median titers and
larger RCD curves for the B1 2014 outbreak virus
with each increasing age group), the highest being
from those in the 2 oldest age groups. Indeed, data
for children >11 years of age were remarkably similar to our previously reported data for children of
these same ages and to our previous data for adults
and elderly persons (21). Titers increasing with patient age suggest EV-D68 exposures during nonoutbreak interval years without detected EV-D68
illnesses. If there had been only a single exposure,
one might expect antibody titers to peak within 6
months and then decline unless re-exposure occurs
(26). Nevertheless, higher titers with age could also
result in part from increasing EV-D68 antibody specificity over time after initial infection.
Although overall B1 virus titers were lowest for
those in the youngest age group (6–35 months), titers were universally >5.0 log2 (≈1:64) even in children born since 2014, also suggesting B1 virus circulation sometime during 2015–2017. Alternatively,
antibodies elicited by exposure to undetected but
related non-B1 viruses may cross-neutralize the tar6

geted viruses (e.g., B1, B2, and D). However crossneutralization activity may be variable, as suggested
by overall differences in titers against B1 virus compared with B2 and D and age-associated differences
for each virus. Of note, B2 and D viruses were not
detected in Kansas City in 2014 (8,10). Indeed, the
low rates of seronegativity to both B2 and the 2014
D virus in our current and prior studies suggest that
antibodies induced by the 2014 B1 virus cross-neutralize B2 and D viruses. Such cross-neutralization
seems reasonable given the close relatedness of the
B1 and B2 viruses and the less but still relatively
close relatedness of the D virus (27).
Comparing our data with data from other serosurveys shows similarities and differences. We confirmed our prior data and that of others (i.e., higher
overall titers in serosurveys performed soon after
outbreak years). A 2011 study from China showed
higher neutralizing titers to locally circulating Beijing/2008/01 EV-D68 in postoutbreak 2011 samples
compared with preoutbreak 2004 samples, despite
few reported EV-D68 illnesses in the Beijing area
during 2009–2011 (16). Likewise, more recent data
from China, Taiwan, the Netherlands, and the United
Kingdom show the same pattern of higher neutralization titers in years soon after outbreaks (20,28).
Similarly, the age-dependent increases in neutralizing titers in this and our previous study (21)
parallel prior data (15,18–20,28,29) regardless of any
temporal relation to outbreak years. Nevertheless,
it was somewhat surprising that titers from 2017 in
Kansas City, even in patients born after the 2014 outbreak, were uniformly >1:64 against the 2014 B1 virus outbreak strain. Furthermore, low neutralizing
titers (defined as <5 log2 or <1:32) were less common
in serum collected in 2017 than in our previously reported samples collected from children during 2012–
2013 (21) against the 2014 major B1 virus (0/300 vs.
54/273 [19.8%]), against B2 virus (110/300 [36.7%] vs.
117/273 [42.9%]), and against D virus (66/300 [22.0%]
vs. 133/273 [48.7%]).
Although differences in the assays used by other investigators (e.g., target virus) make comparing
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absolute titers challenging, our seropositivity rates
for patients 6–35 months of age were also higher than
those found in other studies before and after the 2014
outbreak (15,17,18,28,29). It is possible that the modest EV-D68 activity detected in Kansas City in 2016
led to mild or asymptomatic infections in younger
children and boosted titers in older children.
We also detected higher titers associated with
a history of asthma, but after excluding children
too young to have an asthma diagnosis, we found
significantly higher titers for only the B2 and D viruses. Nevertheless, asthma was the only underlying condition associated with high titers in multivariate analysis. In 2014, severe EV-D68 respiratory
disease occurred in children up to 10 years of age
and in populations with atopic disease, asthma, or
reactive airway disease, despite what seems to have
been the universal presence of neutralizing antibodies, at least in Kansas City children (8,21). This finding suggests that the mere presence of neutralizing
antibodies at a log2 titer >3.0 may not be protective
against disease, at least in some populations. Protection may occur only if sufficient serum neutralizing antibodies are available. For example, severe
respiratory tract disease or AFM is unusual or nonexistent among those in age groups with the highest
overall neutralizing titers: adolescents, adults, or the
elderly (most with titers >1:256 [i.e., log2 >8] in our
current and prior studies [21]).
Of note, in our current study, neutralizing activity against the non-B1 viruses was higher in children
who had asthma as an underlying condition, suggesting an altered response to infection resulting from genetic factors or perhaps to asthma itself (4). For example, asthma is associated with enhanced tight junction
injury from rhinovirus infection (30). Alternatively,
immunopathologic responses may play a role, as can
be seen in the influenza cotton rat model (31). Serum
neutralizing antibodies also may not correlate best
with protection. For example, T-cell activity or mucosal antibodies may be more protective than serum
antibodies (32), or perhaps antibodies to certain epitopes are crucial, as suggested in an EV-D68 mouse
model in which monoclonal antibodies were more
effective than convalescent polyclonal antibodies in
intravenous immunoglobulin preparations (33).
Unlike one previous study (29), we did not find
family size to be associated with seropositivity. We
could not evaluate our prior observation of lower titers in Hispanic patients (21) because of low numbers
of self-reports of ethnicity (41/300). Similarly, we
could not analyze effects of daycare (data available
for only 36/300).

Limitations of our study include a study design
that used salvaged samples and a retrospective chart
review. Because we tested for neutralizing antibodies
against only 3 EV-D68 strains, patterns of neutralizing activity against other EV-D68 strains could differ. However, we did test for the 2014 B1 clade strain
known to have circulated in Kansas City as well as B2
and D viruses. EV-D68 activity in Kansas City during
2016 and 2020 (D) was low but could have boosted
titers. Indeed, we also noted EV-D68 activity in 2018
(B3) and 2020 (clade unknown). Age ranges for our
pediatric groups could be considered arbitrary; the
age groups we used were similar to those used in
our previous study, except we added children 6–35
months of age, paralleling other reports (3). The racial and age distributions of our population matched
those of Kansas City census data and, therefore, might
not be generalizable to other geographic areas. That
said, these distributions closely mirrored those of the
United States as a whole during 2015–2017. Last, the
numbers of patients with each underlying condition
were relatively small, so we may not have had the
power to detect associations (e.g., higher titers to B1
virus in those with asthma).
In conclusion, we detected neutralizing antibodies to the dominant 2014 B1 clade EV-D68 virus at
titers >1:64 for all 300 serum samples from children
in 2017, a time frame with little documented EV-D68
activity since the 2014 outbreak. In the same samples,
overall titers to the less frequently detected B2 and
D viruses were lower. Titers increased with increasing age. Titers against B2 and D virus were higher in
those with asthma. Our findings support the concepts
that an unusual host–virus interaction of EV-D68 occurs in children with asthma and that EV-D68 can
cause disease despite the presence of at least some
neutralizing antibodies.
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